SKSeda Kh. Kurbanova

Seda Kh. Kurbanova

*This is an algorithmically generated author record based on publicly available information.

Seda Kh. Kurbanova has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • EFFECTIVENESS AND SAFETY OF BARICITINIB IN CHILDREN WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY

    by O.L. Lomakina, S.I. Valieva, E.S. Zholobova, S.KH. Kurbanova, D.A. Ermokhina, M.A. Soloshenko

    Baricitinib, a selective Janus kinase 1 and Janus kinase 2 (JAK1/JAK2) inhibitor, was approved by the European Medicines Agency (EMA) in 2023 for the treatment of juvenile idiopathic arthritis (JIA) in children aged 2 years and older. Data on its use in routine clinical practice at Russian pediatric centers remain scarce. Objective: To retrospectively assess the effectiveness and safety of baricitinib in patients with JIA treated at a Russian rheumatology center. Materials and Methods: We conducted a retrospective cohort study at Morozov Children’s City Clinical Hospital. The safety analysis included 41 patients, and the effectiveness analysis included 40 patients. Follow-up lasted up to 12 months, with a median duration of 5.5 months. The primary endpoint was the change in the clinical Juvenile Arthritis Disease Activity Score based on 10 joints (cJADAS10) after 3 months of treatment (visit M3). Assessments were performed at baseline (T0) and at 3 (M3) and 6 (M6) months. Statistical analysis included nonparametric tests for paired comparisons with adjustment for multiple hypothesis testing; confidence intervals for proportions were calculated using the Wilson method. Results: The cohort included 29 girls (71%) and 12 boys (29%). The median age at treatment initiation was 11.9 years [6.2–16.1]; total follow-up was 16.0 patient-years, with a median of 5.5 months [3.2–6.2]. The cJADAS10 decreased from 13.5 [9.2–19.0] at T0 to 8.0 [4.2–11.8] at M3 (n=38; median change, –5.0 [–8.0; –2.0]; p<0.001) and to 2.0 [1.0–10.0] at M6 (n=25; median change, −9.0 [–12.0; –4.0]; p<0.001). Clinically inactive disease was documented in 27 of 36 children (75%) at M3 and in 19 of 28 (68%) at M6. Infections (≥1 episode) occurred in 13 of 41 patients (32%; at least 24 events). No serious adverse events, herpes zoster, or adverse events of special interest were recorded (0/41). Conclusion: Baricitinib treatment was associated with a marked reduction in disease activity and achievement of inactive disease in most patients. No serious adverse events or adverse events of special interest were recorded during follow-up; infections were the most common adverse events. Baricitinib may be an effective and safe treatment option for children with active JIA, although these findings require confirmation in prospective controlled studies.

  • RITUXIMAB USE IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE ANALYSIS OF A CLINICAL CASE SERIES

    by S.I. Valieva, M.S. Kapranova, S.KH. Kurbanova, E.S. Zholobova

    To analyze the efficacy and safety of rituximab therapy in children and adolescents with systemic lupus erythematosus (SLE). Materials and methods. A retrospective analysis of data from 21 patients with SLE (median age 14,0 [10,0; 15,0] years, 81% female) who received at least one rituximab infusion which was performed between 2016 and 2025. The dynamics of the SLEDAI activity index, organ-specific response, glucocorticosteroid dose, laboratory parameters, and the frequency of adverse events were assessed at 6 and 12 months of follow-up. Results. Rituximab therapy resulted in a statistically significant reduction in the SLEDAI index from 16,5 [11,0; 18,8] to 2,0 [2,0; 4,0] points at 6 months and to 2,0 [0,5; 2,0] points at 12 months (p<0,001). Low disease activity (SLEDAI ≤5) at 12 months was achieved in 95% of patients. A significant decrease was noted in the daily prednisolone dose from 40,0 [31,3; 50,0] to 15,0 [10,0; 20,0] mg (p=0,002) and in the weight-adjusted prednisolone dose from 1,00 [1,00; 1,00] to 0,26 [0,21; 0,32] mg/kg/day (p<0,001). Complete organ-specific response was achieved in 85,7% of patients. A significant reduction in immunoglobulin levels (IgG, IgM, IgA) was recorded (p≤0,001). Adverse events were observed in 28,6% of patients, with hypogammaglobulinemia requiring intravenous immunoglobulin being the most frequent. One fatal outcome (4,8%) occurred in a female patient with refractory SLE and multiorgan involvement. Conclusion. Rituximab demonstrated high clinical efficacy in controlling disease activity and a steroid-sparing effect in children with SLE. The safety profile of the drug was consistent with global data and requires careful monitoring for infectious complications and immunoglobulin levels.

  • VACCINATION COVERAGE IN CHILDREN WITH RHEUMATIC AND IMMUNE-MEDIATED INFLAMMATORY DISEASES: A RETROSPECTIVE COHORT STUDY

    by O.L. Lomakina, S.I. Valieva, E.S. Zholobova, S.KH. Kurbanova, M.A. Soloshenko

    Children with immune-mediated inflammatory diseases receiving immunosuppressive therapy are at increased risk of vaccine-preventable infections. Despite the availability of international recommendations on vaccination for this patient population, data on real-world immunization coverage in the Russian pediatric population are limited. Objective: To assess vaccination coverage in children (0–17 years inclusive) with rheumatic and immune-mediated inflammatory diseases before and after diagnosis, and to identify factors associated with immunization coverage. Materials and Methods: A single-center retrospective cohort study was conducted, including 336 patients with autoimmune diseases. Results: The study included children aged 0 to 17 years, with a median age of 14.1 years [11.1; 16.4]. Females predominated: 203/336 (60.4%) vs 133/336 (39.6%). Coverage with basic vaccines ranged from 82% to 87%: DTP components – pertussis 84.2% (95% CI 79.9–87.8), diphtheria 87.2% (83.2–90.4), tetanus 85.1% (80.9–88.5); polio – 83.9% (79.6–87.5); measles, rubella, mumps – 81.2% (76.7–85.1); BCG – 81.5% (77.1–85.3); hepatitis B – 82.4% (78.0–86.1). In contrast, vaccination coverage against respiratory pathogens remained low: pneumococcal infection – 23.5% (19.3–28.3), influenza – 20.2% (16.3–24.9). Therapy with biologic disease-modifying antirheumatic drugs (bDMARDs) showed no statistically significant association with influenza vaccination after the onset of immune-mediated inflammatory disease (OR 0.53; 95% CI 0.20–1.42; p=0.208). Conclusion: High coverage with basic National Immunization Schedule vaccines (81–87%) was found, with a substantial lag in coverage for vaccines most important for patients with potential immunosuppression. These findings support the integration of preventive vaccination into the standard patient pathway for immune-mediated inflammatory diseases, with a clear distribution of responsibility among specialists and regular verification of vaccination status.

  • Open Access

    Acute rheumatic fever — a late complication of streptococcal infection: results of a 25-year study

    by Yu. Yu. Novikova, M. G. Kantemirova, O. A. Korovina, M. A. Abramyan, S. I. Valieva, А. Е. Кессель, I. N. Kiseleva, S. Kh. Kurbanova, S. S. Paunova, D. Yu. Ovsyannikov, et al.

    Despite a decline in incidence, acute rheumatic fever (ARF) and recurrent ARF is a late autoimmune complication of S. pyogenes infection — remain a significant public health problem, being a cause of chronic rheumatic heart disease. Objective : to provide a clinical and epidemiological characterization and describe the outcomes of ARF based on observations of patients hospitalized between 2001 and 2025 at the Morozovskaya children’s city clinical hospital of the Moscow Department of Health. Materials and methods . We observed 113 children (60 girls, 53 boys), aged 4—17 years (median age 10 [8; 13] years), with a diagnosis of ARF (101 children) or recurrent ARF (12 children). We assessed clinical and anamnestic data, laboratory test results (antistreptolysin-O (ASO), C-reactive protein), electrocardiography (ECG), and echocardiography. Children with Sydenham's chorea underwent additional examinations. Results. A high rate of underdiagnosis of ARF was identified (63.7%). The onset of ARF most commonly occurred during the winter-spring period (61.9 %). To confirm markers of previous streptococcal infection, measuring ASO levels is more informative; an elevated ASO level (median 795 [385; 1440] IU/mL) was detected in 86.7% of children. In theclinical presentation of ARF, carditis was the predominant manifestation (81.4 %), and its frequency increased with age (p = 0,003). The mitral valve (MV) was most commonly affected (54%); combined involvement of the MV and aortic valve (AV) was observed in 34.5% of children, while isolated AV involvement occurred in 11.5 %. Arthritis was detected in 44.2% of children, with a high frequency (36/50, 72%) of atypical joint syndrome. Our study recorded a high incidence of Sydenham's chorea (56 children, 49.6%), including isolated Sydenham's chorea in 30.4%. The incidence of Sydenham's chorea decreased with age (p = 0,004). Rare manifestations of ARF — erythema marginatum and subcutaneous nodules — were observed in 14.2% and 3.4% of patients, respectively. A high incidence of chronic rheumatic heart disease (42%) was noted, with the development of rheumatic heart valve defects in 38% of cases. Conclusion . The study highlights the need for vigilance regarding ARF in patients following streptococcal infection to prevent severe outcomes such as the development of acquired heart valve defects.

  • Clinical case report of facial neuritis, a rare manifestation of Kawasaki disease

    by Moscow Morozov Children’s City Clinical Hospital, S.KH. Kurbanova, M.G. Kantemirova, S.I. Valiyeva, A.D. Bryk, Yu.YU. Novikova, A.S. Sologub, M.M. Kurako, V.V. Gorev

    Kawasaki disease (KD) is an acute systemic disease characterized by predominant damage to small and medium-sized arteries with the development of destructive-proliferative vasculitis, damage to the coronary (CA) and visceral arteries. In addition to the symptoms included in the diagnostic criteria for KD, other clinical manifestations are observed in the Article. Facial nerve damage in KD is a rare but serious manifestation which can be a marker for severe CA damage. Authors represent their own clinical case report of a 5-months-old male patient with late diagnosis of immunoglobulin-resistant KD with giant aneurysms of CA and facial nerve paralysis.

  • Monogenic autoinflammatory diseases: a bibliographical review of its modern concepts

    by Moscow Morozov Children’s City Clinical Hospital, S.I. Valiyeva, S.KH. Kurbanova, D.YU. Ovsyannikov

    Autoinflammatory diseases (AIDs) are a group of rare disorders characterized by recurrent episodes of inflammation with neither infectious nor autoimmune nor neoplastic trigger. The AIDs pathogenesis is based on mutations in genes that lead to uncontrolled and excessive production of proinflammatory cytokines. Authors represent current views on the pathogenesis, clinical manifestations, diagnosis and treatment of the most studied monogenic AIDs. New therapeutic approaches based on targeted blockade of key inflammatory mediators are described as well.

  • Genotypic and phenotypic characteristics of pediatric patients with familial Mediterranean fever (a periodic disease) in one of the Russia regions

    by Moscow Morozov Children’s City Clinical Hospital, S.I. Valiyeva, S.KH. Kurbanova, I.R. Gaziyev, D.YU. Ovsyannikov

    Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease (AID) caused by mutations in the MEFV gene. The purpose of this research was to investigate clinical variability and potential genotypic and phenotypic correlations in children with clinically verified FMF and MEFV gene mutations in the City of Moscow, Russia. Materials and methods used: among 188 pediatric patients with suspected monogenic AIDs, MEFV gene mutations were identified in 9 through sequencing. In order to confirm the FMF diagnosis, patients were evaluated according to the modified Tel-Hashomer criteria and the Eurofever/PRINTO classification criteria. Results: clinical picture of FMF was characterized by the presence of periodic attacks of the disease lasting from 1 to 7 days accompanied by fever and increased acute phase reactants (observed in all patients), abdominal pain (in 8 children), peritonitis requiring diagnostic laparotomy (in a single child), chest pain (in 2 patients), pleurisy (in a single child), arthritis (in 7 children) and erysipeloid-like rash (in a single child). The pathogenic mutation M694V was identified in the MEFV gene in 8 out of 9 patients, this mutation was homozygous in 5 patients and heterozygous in 1, M680I mutation was detected on another allele in 2 children (compound heterozygous), and a mutation of unknown significance K695R was detected in a single child. No obvious clinical differences were found between homozygotes and heterozygotes as well as compound heterozygotes. Clinical response was achieved in 5 patients with colchicine monotherapy while canakinumab was prescribed to 4 patients due to ongoing attacks. Conclusion: the diagnosis involving the identification of MEFV gene mutations may allow the assessment of genotype-phenotype correlations in patients with FMF.

  • Clinical and epidemiological features of the systemic lupus erythematosus in children: observational data obtained and systemized at the Morozov Children’s City Clinical Hospital (Moscow, Russia)

    by Moscow Morozov Children’s City Clinical Hospital, S.I. Valiyeva, M.S. Kapranova, S.KH. Kurbanova, E.A. Korobyants, A.K. Nargizyan, M.S. Dzis, A.O. Marandzhyan

    Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of unknown etiology characterized by hyperproduction of autoantibodies. The problems of timely diagnosis and identification of predictors of an unfavorable outcome of SLE are relevant due to the variable clinical picture and a high risk of 5-year mortality in the absence of treatment. The purposes of this research were to assess the frequency of various variants of SLE onset, to identify trigger factors contributing to the development of the disease and to analyze the degree of disease activity in children. Materials and methods used: a single-center cohort retrospective study was conducted involving patients aged 9 to 17 y/o who had undergone inpatient treatment at the rheumatological department of the Morozov Children’s City Clinical Hospital (Moscow, Russia) in 2020-2023, specifying age, gender, assessing the frequency of observed symptoms of SLE onset, disease activity according to the SLEDAI scale, laboratory parameters and drug treatment. Results: total of 45 records were analyzed: 75.5% (34) girls/24.5% (11) boys; median age 15 [13; 15] y/o; most frequent clinical syndrome was cutaneous (75.5%); kidney damage was noted in 40% of cases. 86.6% had hematological disorders as follows: thrombocytopenia and leukopenia (48.9%), anemia (46.6%): Coombs-positive anemia (71.4%), lymphopenia (37.7%) and increased ESR (66.6%). Antinuclear factor (ANF Hep2) was detected in all cases. According to the SLEDAI-2K scale, the median disease activity was 11 [7; 16] points. Low disease activity (less than 6 points) was observed in 4.4% (2), average (6 to 10 points) in 44.4% (20), high (11 to 19 points) in 37.7% (17), above average (over 20 points) in 13.3% (6). Moreover, disease activity was higher in girls (p=0.940) and a relationship was found between the time required for diagnosis and disease activity according to the SLEDAI-2K scale (p=0.206). Drug therapy: glucocorticoids (GCS) orally in all cases, intravenous pulse GCS therapy in 71.0%. Hydroxychloroquine therapy was prescribed in 100.0%, mycophenolate mofetil in 57.7%, intravenous immunoglobulin in 37.7%, cyclophosphamide in 13.3%, methotrexate in 6.6%, biological therapy in 31.0%, the drug of choice was rituximab. Conclusion: updating the data on the frequency of various variants of SLE debut as well as identifying the new trigger factors contributing to the development of the disease are necessary steps aiming to increasing the awareness of the SLE course with its debut in childhood, optimizing the diagnosis process and reducing the risk for complications.

  • SYSTEMIC-ONSET JUVENILE ARTHRITIS: EPIDEMIOLOGY, CLINICAL PICTURE, DIFFERENTIAL DIAGNOSIS IN PHYSICIAN’S PRACTICE (RESULTS OF A TWO-CENTER RETROSPECTIVE COHORT STUDY)

    by V.T. Yusupova, E.S. Zholobova, S.Kh. Kurbanova, M.N. Nikolaeva, V.A. Seraya, E.Yu. Afonina, A.K. Nargizyan, S.I. Valieva, Moscow Morozov Children’s City Clinical Hospital

  • CARDIOVASCULAR SYSTEM LESIONS, RISK FACTORS AND PREDICTORS FOR ADVERSE OUTCOMES IN CHILDREN WITH KAWASAKI DISEASE

    by S.Kh. Kurbanova, Moscow Morozov Children’s City Clinical Hospital, M.G. Kantemirova, A.A. Glazyrina, Yu.Yu. Novikova, O.A. Korovina, S.I. Valieva, M.A. Abramyan, V.V. Gorev, D.Yu. Ovsyannikov